|
|
|
@ -0,0 +1,14 @@ |
|
|
|
Metandienone Wikipedia |
|
|
|
<br>Key Take‑away |
|
|
|
<br> |
|
|
|
<br>Metabolite‑based oral agents that act on the androgen receptor are typically prescription‑only drugs with a narrow therapeutic window. They are approved for specific clinical indications, have well‑characterised pharmacokinetics and a defined safety profile, but carry significant risks of hormonal side‑effects and may be abused or diverted in non‑clinical settings.<br> |
|
|
|
<br> |
|
|
|
<br>Below is a concise "cheat sheet" that covers the major aspects you need to know as a healthcare professional. |
|
|
|
<br> |
|
|
|
<br>--- |
|
|
|
<br> |
|
|
|
1. FDA/EMA Approved Indications |
|
|
|
|
|
|
|
DrugApproved Uses (U.S.)Expanded Uses (Europe) |
|
|
|
Enobosarm (Ovolutamab)Investigational – early‑phase trials for androgenic alopecia and sarcopeniaPhase II studies: breast cancer, muscle wasting |
|
|
|
TirbanibulinNot a SARM |
